临床试验/NCT02633189

NCT02633189进行中（未招募）3 期

A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

National Cancer Institute, Naples55 个研究点分布在 1 个国家目标入组 200 人开始时间: 2016年4月最近更新: 2023年3月24日

适应症

干预措施

试验速览

阶段: 3 期
状态: 进行中（未招募）
发起方
入组人数: 200
试验地点: 55
主要终点: progression free survival

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to test whether the combination of bevacizumab and erlotinib can prolong progression free survival as compared with erlotinib alone as first-line treatment in patients with non small cell lung cancer (NSCLC) with activating mutation of EGFR.

详细描述

The co-primary objectives are to assess investigator-assess, and blinded independent centrally-reviewed progression-free survival .

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age ≥18 years
•Histological documentation of primary non squamous lung carcinoma
•Stage IV or IIIB disease with supraclavicular metastatic nodes (according to TNM 7th edition)
•Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations, such as exon 21 L861Q, exon 18 G719S, G719A and G719C, exon 20 S768I and V769L). EGFR mutation testing must be performed at participating centres in a certified lab (AIOM-SIAPEC program or other European Quality Assurance [EQA] schemes)
•Clinical or radiologic evidence of disease (at least one target or non target lesion according to RECIST 1.1)
•ECOG performance status 0 to 2
•Life expectancy > 3 months
•Use of an acceptable mean of contraception for men and women of childbearing potential
•Written informed consent.

排除标准

•EGFR T790M mutation alone or exon 20 insertions as unique mutation
•Tumors with a squamous component
•Prior chemotherapy or any other medical treatment for advanced NSCLC (previous neoadjuvant or adjuvant chemotherapy is allowed if > 6 months before randomisation)
•Radiotherapy to any site for any reason within 28 days prior to randomization (palliative radiotherapy to bone lesions is allowed if ≥ 14 days before randomization)
•Full-dose anticoagulation with warfarin
•Current or recent (within 10 days of enrolment) use of aspirin (>325 mg/day) or chronic use of other full-dose nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-platelet activity
•Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450 3A4 (CYP3A4) are prohibited =< 7 days prior to registration
•Receiving any medications or substances that are inducers of CYP3A4 use of inducers are prohibited =< 7 days prior to registration
•Inadequate coagulation parameters:
•activated partial thromboplastin time (APTT) >1.5 x the upper limit of normal (ULN) or
•INR >1.5
•Inadequate liver function, defined as:
•serum (total) bilirubin >1.5 x ULN
•AST/SGOT or ALT/SGPT >2.5 x ULN
•Inadequate renal function, defined as:
•serum creatinine >2.0 mg/dl or >177 micromol/l
•urine dipstick for proteinuria >2+. Patients with > o = 1+ proteinuria at baseline dipstick analysis must undergo a 24-hour urine collection and must demonstrate ≤1g of protein in their 24-hour urine collection.
•Pregnancy or breast-feeding
•Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure >100 mmHg on antihypertensive medications)
•History of gross hemoptysis within 3 months prior to randomization unless definitively treated with surgery or radiation
•History of any of the following within 6 months prior to randomisation: serious systemic disease, unstable angina, New York Heart Association (NYHA) Grade 2 or greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
•Serious, non-healing wound, ulcer, or bone fracture
•Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior to randomization
•Central Nervous System (CNS) bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic) within the last 6 months
•In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
•Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior to randomization
•Anticipation of need for a major surgical procedure during the course of the study
•Inability to take oral medication or requirement for intravenous (IV) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption
•Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Informed Consent Form or his/her ability to comply with study requirements
•Any other invasive malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA)
•Brain metastasis
•Patients who have had radiotherapy ≥ 4 weeks prior to the first dose of study treatment, but who are still experiencing acute toxic effects of radiotherapy
•Known HIV positive patients (patients with both acute or chronic infection are excluded)
•Active HBV or HCV infection (patients with chronic non-active infection are eligible)
•Any already known inflammatory changes of the surface of the eye at baseline
•Any other concomitant pathologies or laboratory alterations that prevent or contraindicate the use of erlotinib or bevacizumab.

研究组 & 干预措施

erlotinib and bevacizumab

Experimental

干预措施: Erlotinib (Drug)

erlotinib and bevacizumab

Experimental

干预措施: Bevacizumab (Drug)

erlotinib

Active Comparator

干预措施: Erlotinib (Drug)

结局指标

主要结局

progression free survival

时间窗: up to 2 years

as determined by an independent central review board blinded to study treatment

次要结局

worst grade toxicity per patient(up to one year)
progression free survival according to type of EGFR mutation (exon 19del, exon 21L858R, other)(2 years)
overall survival(1 year)
number of patients with complete and partial responses , investigator assessed(6 months)
changes in quality of life scores from baseline(up to 2 years)
number of patients with complete and partial responses , centrally reviewed(6 months)

研究者

发起方

National Cancer Institute, Naples

申办方类型

Other

责任方

Sponsor

研究点 (55)

Loading locations...

相似试验

Unknown

3 期

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationNon-Small Cell Lung Cancer

NCT02001896Xinjiang Medical University60

已完成

3 期

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)Metastatic Colorectal Cancer

NCT04456699Merck Sharp & Dohme LLC335

已完成

2 期

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderGastrointestinal CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer

NCT00356889National Cancer Institute (NCI)56

已完成

2 期

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus ErlotinibProstate Cancer

NCT00203424Translational Oncology Research International23

已完成

1 期

NCT00055913National Cancer Institute (NCI)58